Tofacitinib for the treatment of severe rare skin diseases: a narrative review.
Purpose: Autoimmune bullous diseases, connective tissue diseases, and vasculitis represent a group of severe rare skin diseases. While glucocorticoids and immunosuppressive agents serve as standard treatments for these diseases, their efficacy is limited due to adverse side effects, indicating the n...
| Published in: | European Journal of Clinical Pharmacology Vol. 80; no. 4; pp. 481 - 493 |
|---|---|
| Main Authors: | , , |
| Format: | review tables/charts Journal Article |
| Published: |
Springer Nature
Apr2024
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=176033245&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 176033245 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Apr2024 vid: 80 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 176033245 174833287 176033245 176033245 10.1007/s00228-024-03621-9 176033245 ppf: 481 ppct: 12 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Tofacitinib for the treatment of severe rare skin diseases: a narrative review. aug: au: Luo, Fenglin Zhang, Yuanyuan Wang, Ping affil: Department of Dermatology, Hangzhou Third People's Hospital, 310000, Hangzhou, China sug: subj: Janus Kinase Inhibitors Therapeutic Use Janus Kinase Inhibitors Pharmacodynamics Drug Efficacy Patient Safety Severity of Illness Rare Diseases Drug Therapy Pemphigoid, Bullous Drug Therapy Connective Tissue Diseases Drug Therapy Vasculitis Drug Therapy Skin Diseases Drug Therapy Glucocorticoids Therapeutic Use Immunosuppressive Agents Therapeutic Use Glucocorticoids Adverse Effects Immunosuppressive Agents Adverse Effects Biological Products Therapeutic Use Disease Management Biological Products Economics Biological Products Adverse Effects Cost Effectiveness Analysis Signal Transduction Drug Effects STAT Proteins Drug Effects Janus Kinase Inhibitors Adverse Effects ab: Purpose: Autoimmune bullous diseases, connective tissue diseases, and vasculitis represent a group of severe rare skin diseases. While glucocorticoids and immunosuppressive agents serve as standard treatments for these diseases, their efficacy is limited due to adverse side effects, indicating the need for alternative approaches. Biologics have been used in the management of some rare skin diseases. However, the use of biologics is associated with concerns, such as infection risk and high costs, prompting the quest for efficacious and cost-effective alternatives. This study discusses the safety issues associated with tofacitinib and its potential in treating rare skin diseases. Methods: This narrative review focuses on the pharmacodynamic properties of tofacitinib and its impact on the JAK/STAT pathway. In addition, we present a comprehensive discussion of the effects and mechanism of action of tofacitinib for each severe rare skin disease. Results: This role of tofacitinib in treating severe rare skin diseases has been discussed, shedding light on its promising prospects as a treatment modality. Few reports of serious adverse events are available in patients treated with tofacitinib. Conclusion: We explored the mechanism of action, efficacy, and safety considerations of tofacitinib and found that it can be used as a treatment option for rare skin diseases. However, multicenter clinical studies are needed to confirm the efficacy and safety of JAK inhibitors. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|